Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

BRACAnalysis to be Used as Companion Diagnostic for AstraZeneca's Olaparib SALT LAKE CITY, April 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has submitted the first module of a premarket approval (PMA) application to the Food and Drug Administration (FDA) for the use of BRACAnalysis(®) testing as a companion diagnostic with olaparib...

New York, 07/04/2014 (informazione.news - comunicati stampa - varie)

BRAC Analysis to be Used as Companion Diagnostic for AstraZeneca's Olaparib

Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire